About Us Strategy & Mission Our Values Our People Our Board Our Collaborations Contact Our Programmes Overview Pipeline C. difficile Infection Gonorrhoea Enterobacteriaceae ESKAPE Programme Clinical Trials Stewardship Compassionate Use Our Science Discuva Platform Publications Investors Investor Centre Press Releases Financial Reports & Filings Email Alerts Events & Presentations Share Price Data Analyst Coverage Corporate Governance Shareholder Meetings Careers
Ridinilazole for Clostridium difficile Infection: Human Gut Microbiome Profiles from a Phase 2 Clinical Trial Ridinilazole for Clostridium difficile Infection: Human Gut Microbiome Profiles from a Phase 2 Clinical Trial October 3, 2018 By Mary Alvarado
Ridinilazole for Clostridium difficile Infection: Human Gut Microbiome Profiles from a Phase 2 Clinical Trial
Ridinilazole for Clostridium difficile Infection: Human Gut Microbiome Profiles from a Phase 2 Clinical Trial October 3, 2018 By Mary Alvarado
